Liabilities / Assets
70th percentile
Higher debt load relative to assets than 70% of similar nonprofits.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.22x
Liabilities / Revenue
79th percentile
Higher debt load relative to revenue than 79% of similar nonprofits.
Net Margin
97th percentile
Higher net margin than 97% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
97th percentile
Faster asset growth than 97% of similar nonprofits.
Revenue Growth
94th percentile
Faster revenue growth than 94% of similar nonprofits.
Balance Sheet
Assets
Up$544,966
Up $417,567 (+328%) from 2019
Net Assets
Up$425,261
Up $297,862 (+234%) from 2019
Liabilities
Up$119,705
Up $119,705 from 2019
Revenue And Expenses
Revenue
Up$346,976
Up $196,650 (+131%) from 2019
Expenses
Up$49,114
Up $26,187 (+114%) from 2019
Net Income
Up$297,862
Up $170,463 (+134%) from 2019
Historical Trend
Filing Detail Status
This 2020 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jul 1, 2019 to Jun 30, 2020
Mission and Program Overview
Mission
Our mission is to connect families, resources, and the medical community to advance research for a cure to ddx3x gene mutations. Our ultimate goal over the coming years is to accelerate brain function in individuals affected by ddx3x through advances in gene therapy and pharmaceuticals.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2020 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $544,966
- Liabilities
- $119,705
- Net assets
- $425,261
- Revenue
- $346,976
- Expenses
- $49,114
- Net income
- $297,862